Pancreatic Cancer Q&A with Dr. Stauffer, Mayo Surgeon: May 29
Allow me to introduce you to Dr. John Stauffer, a hepatobiliary and pancreas surgical oncologist at Mayo Clinic in Florida, one of the country's highest-volume surgical programs for advanced pancreatic cancer.
On Thursday, May 29 from 1:30-2:30pm ET, Dr. Stauffer will host a Q&A about surgical management of pancreatic cancer.
After a pancreatic cancer diagnosis, many people have questions about treatment options, including surgical and nonsurgical approaches. You may also want to know how an integrated team – including surgical oncology, medical oncology, radiation oncology and gastroenterology specialists – works together to prevent further cancer complications and preserve your quality of life.
Please note that this hour-long Q&A is for informational purposes only, and any concerns you have should be addressed to your treating physician. If you would like to learn about pancreas cancer care at our integrated program in Florida, please visit this page for information.
Submit your questions in advance in the comments below and Dr. Stauffer will reply during the hour-long Q&A event. See you back here on May 29.
Go ahead, ask away!
Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.
Not to my knowledge.
Unfortunately, current immunotherapy is only helpful for a very small percentage of PDAC patients with microsatellite instability high tumors.
It depends on the tumor type, biology, location, and treatment response. Overall, liver lesions are very complex and require a multidisciplinary team to treat. Seeing a single person can be limiting because that single person oftentimes only offers what they can do. Seeing a whole team of people (like here at Mayo Clinic) is an advantage because we offer whatever treatment is best for the patient no matter who of the team can deliver it.
The growth rate is relative. PDAC is an aggressive and fast growing cancer overall but some people may call 1-3 years slow growing. It is oftentimes only detected in the final stages where it appears to progress rapidly but in fact had been developing for several years.
Each clinical trial have their own inclusion and exclusion criteria but all of them will have concessions that would allow for alternating the treatment plan (or leaving a trial) if a more effective method would become available.
Each case is highly unique, but we generally have a surgical treatment plan if the tumor is localized, not metastatic, and has shown good biology even if there is vein or arterial involvement.
It depends on the tumor type, biology, location, and treatment response. Overall, liver lesions are very complex and require a multidisciplinary team to treat. Seeing a single person can be limiting because that single person oftentimes only offers what they can do. Seeing a whole team of people (like here at Mayo Clinic) is an advantage because we offer whatever treatment is best for the patient no matter who of the team can deliver it.
We use SBRT frequently for our resectable PDAC patients. SBRT in the setting of metastatic is controversial and unlikely to provide anything other than side effects except in very special circumstances (1 or 2 isolated sites of disease after prolonged systemic therapy) and under a clinical trial.
We at Mayo Clinic in Florida use IRE for unresectable PDAC in combination with systemic chemotherapy and radiation treatment. This modality is not widely used or have available trials due to the lack of efficacy against cancer when compared to standard treatment. It is employed occasionally for patients who are not candidates for standard treatment. IRE should only be used for patients that have no other options based on sound evidence, not for theoretical benefits touted by the manufacturer or those who stand to gain financially from its use.
Yes, I have used the Nanoknife over the past 6 years to help treat patients with unresectable PDAC.
Nanonkife and total pancreatectomy are used occasionally, but not if they do not offer a better outcome with less chance of recurrence than any other type of operation. Yes, adjuvant therapy is almost always recommended.